In silico binding free energy predictability by using the linear interaction energy (LIE) method: bromobenzimidazole CK2 inhibitors as a case study.
Protein kinase CK2 is essential for cell viability, and its control regards a broad series of cellular events such as gene expression, RNA, and protein synthesis. Evidence of its involvement in tumor development and viral replication indicates CK2 as a potential target of antineoplastic and antiviral drugs. In this study the Linear Interaction Energy (LIE) Method with the Surface Generalized Born (SGB) continuum solvation model was used to study several bromobenzimidazole CK2 inhibitors. This methodology, developed by Aqvist, finds a plausible compromise between accuracy and computational speed in evaluating binding free energy (DeltaGbind) values. In this study, two different free binding energy models, named "CK2scoreA" and "CK2scoreB", were developed using 22 inhibitors as the training set in a stepwise approach useful to appropriately select both the tautomeric form and the starting binding position of each inhibitor. Both models are statistically acceptable. Indeed, the better one is characterized by a correlation coefficient (r2) of 0.81, and the predictive accuracy was 0.65 kcal/mol. The corresponding validation, using an external test set of 16 analogs, showed a correlation coefficient (q2) of 0.68 and a prediction root-mean-square error of 0.78 kcal/mol. In this case, the LIE approach has been proved to be an efficient methodology to rationalize the difference of activity, the key interactions, and the different possible binding modes of this specific class of potent CK2 inhibitors.
Bortolato
A
A
Molecular Modeling Section, Department of Pharmaceutical Sciences, University of Padova, via Marzolo 5, I-35131 Padova, Italy.
Moro
S
S
D001562:Benzimidazoles / Q000737:chemistry*; D001665:Binding Sites; D047390:Casein Kinase II / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D019295:Computational Biology / Q000379:methods*; D018360:Crystallography, X-Ray; D006801:Humans; D006842:Hydrocarbons, Brominated / Q000737:chemistry*; D020128:Inhibitory Concentration 50; D015394:Molecular Structure; D012997:Solvents; D013329:Structure-Activity Relationship; D014867:Water / Q000737:chemistry
D001562:Benzimidazoles; D006842:Hydrocarbons, Brominated; D012997:Solvents; D014867:Water; D047390:Casein Kinase II